International Journal of Cancer and Oncology
B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma: A Review of Reported Cases
- 1Pharmacology Department; College of Medicine and Health Sciences-UAE University, UAE
- 2Senior Pharmacist, Tawam Hospital, Abu Dhabi Health Services-UAE
Omar Nadeem, Brown University, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903, USA, Tel: 401444.5435 ; Fax: 401.444.5256 ; E-mail: email@example.com
Nadeem, O., et al. B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma: A Review of Reported Cases. (2014) J Cancer Oncol 1(1): 1-4.
© 2014 Nadeem, O. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
KeywordsGrey zone; Unclassifiable; Lymphoma
Grey Zone Lymphoma (GZL), with features intermediate between classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL), is a new entity with limited reported data. A MEDLINE search through July 2013 identified 39 cases of GZL and two additional cases were added from our institution. Comparison of complete remission (CR) rates between ABVD and CHOP-based regimens was performed using Fisher’s exact test. The median age of presentation was 33.5 years with a male predominance (59%), mediastinal involvement (89%), and early stage disease (75%). Patients treated with CHOP-based regimens achieved higher CR rates compared to initial ABVD-based regimens (80% vs. 0%;p=0.01). The 2-yr OS was 87% with a median OS that was not reached. Our reviewindicates this lymphoma subtype to have a high incidence of early stage presentation, mediastinal involvement, B symptoms and overall better outcomes with CHOP-based regimens. Additional studies are warranted to further study this disease.